Search Results
You are looking at 1 - 1 of 1 items for
- Author: Qinkai Li x
- Refine by access: All content x
Key Laboratory for Atherosclerology of Hunan Province, Department of Nutrition and Metabolism, Clinical Research Center for Diabetes, Institute of Cardiovascular Research, Life Science Research Center, University of South China, Hengyang, Hunan 421001, People's Republic of China
Key Laboratory for Atherosclerology of Hunan Province, Department of Nutrition and Metabolism, Clinical Research Center for Diabetes, Institute of Cardiovascular Research, Life Science Research Center, University of South China, Hengyang, Hunan 421001, People's Republic of China
Search for other papers by Qinkai Li in
Google Scholar
PubMed
Search for other papers by Weidong Yin in
Google Scholar
PubMed
Search for other papers by Manbo Cai in
Google Scholar
PubMed
Search for other papers by Yi Liu in
Google Scholar
PubMed
Search for other papers by Hongjie Hou in
Google Scholar
PubMed
Search for other papers by Qingyun Shen in
Google Scholar
PubMed
Search for other papers by Chi Zhang in
Google Scholar
PubMed
Search for other papers by Junxia Xiao in
Google Scholar
PubMed
Search for other papers by Xiaobo Hu in
Google Scholar
PubMed
Search for other papers by Qishisan Wu in
Google Scholar
PubMed
Search for other papers by Makoto Funaki in
Google Scholar
PubMed
Search for other papers by Yutaka Nakaya in
Google Scholar
PubMed
Insulin resistance and dyslipidemia are both considered to be risk factors for metabolic syndrome. Low levels of IGF1 are associated with insulin resistance. Elevation of low-density lipoprotein cholesterol (LDL-C) concomitant with depression of high-density lipoprotein cholesterol (HDL-C) increase the risk of obesity and type 2 diabetes mellitus (T2DM). Liver secretes IGF1 and catabolizes cholesterol regulated by the rate-limiting enzyme of bile acid synthesis from cholesterol 7α-hydroxylase (CYP7A1). NO-1886, a chemically synthesized lipoprotein lipase activator, suppresses diet-induced insulin resistance with the improvement of HDL-C. The goal of the present study is to evaluate whether NO-1886 upregulates IGF1 and CYP7A1 to benefit glucose and cholesterol metabolism. By using human hepatoma cell lines (HepG2 cells) as an in vitro model, we found that NO-1886 promoted IGF1 secretion and CYP7A1 expression through the activation of signal transducer and activator of transcription 5 (STAT5). Pretreatment of cells with AG 490, the inhibitor of STAT pathway, completely abolished NO-1886-induced IGF1 secretion and CYP7A1 expression. Studies performed in Chinese Bama minipigs pointed out an augmentation of plasma IGF1 elicited by a single dose administration of NO-1886. Long-term supplementation with NO-1886 recovered hyperinsulinemia and low plasma levels of IGF1 suppressed LDL-C and facilitated reverse cholesterol transport by decreasing hepatic cholesterol accumulation through increasing CYP7A1 expression in high-fat/high-sucrose/high-cholesterol diet minipigs. These findings indicate that NO-1886 upregulates IGF1 secretion and CYP7A1 expression to improve insulin resistance and hepatic cholesterol accumulation, which may represent an alternative therapeutic avenue of NO-1886 for T2DM and metabolic syndrome.
